EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study

Daiki Sakai, Kaichi Kaneko, Karin Furukawa, Mai Kawazoe, Yasuo Matsuzawa, Toshihiro Nanki

Rheumatology International · 2025

DOI: 10.1007/s00296-025-05991-4 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Rheumatology International, 2025. Verfasst von Daiki Sakai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo, 143-8540, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glucocorticoids, Immunosuppressive Agents, Granulomatosis with Polyangiitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mepolizumab (MPZ) is an anti-interleukin-5 monoclonal antibody used to treat eosinophilic granulomatosis with polyangiitis (EGPA). This study aimed to compare the efficacy of MPZ and conventional treatment (CT) for EGPA after maintenance therapy initiation. In this retrospective, observational study, patients diagnosed with EGPA meeting these criteria were included: prednisolone ≤ 20 mg/day, Birmingham Vasculitis Activity Score (BVAS) < 10, and MPZ or new CT initiation ≥ 6 months after initial treatment were included (MPZ: n = 16; CT: n = 16). BVAS, relapse-free survival, absolute eosinophil count, cumulative glucocorticoids (GC) dose, and GC toxicity index (GTI) were evaluated for up to 12 months. Multivariable linear regression for BVAS and logistic regression for relapse at 12 months were performed, adjusting for age, gender, disease duration, and baseline eosinophil count. In the MPZ group, BVAS at 12 months significantly decreased, while BVAS tended to be lower in the MPZ than in the CT group at 12 months. Participants achieving BVAS = 0 significantly increased in the MPZ group at 12 months. Relapse rates tended to be lower in the MPZ group. Absolute eosinophil counts decreased in the MPZ compared with the CT group from 1 to 12 months. Cumulative GC dose and GTI significantly decreased in the MPZ group vs. CT group. In multivariable analyses, the use of MPZ was suggestive of lower BVAS and lower odds of relapse at 12 months compared with CT, although these differences were not statistically significant. MPZ could be a potential treatment option for reducing GC or improving residual symptoms in patients with EGPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlucocorticoidsImmunosuppressive AgentsGranulomatosis with PolyangiitisChurg-Strauss SyndromeHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedPrednisoloneRecurrence

Stichwörter der Autor:innen

Disease managementEosinophilic granulomatosis with polyangiitisGlucocorticoidsImmunosuppressive agentsInterleukin-5Mepolizumab

Substanzen

Antibodies, Monoclonal, HumanizedmepolizumabGlucocorticoidsImmunosuppressive AgentsPrednisolone

Autor:innen und Institutionen

  • Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo, 143-8540, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, 285-8741, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, 285-8741, Japan.
  • Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo, 143-8540, Japan. ihciakokenak@med.toho-u.ac.jp.
  • Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, 285-8741, Japan. ihciakokenak@med.toho-u.ac.jp.
  • Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, 143-8541, Japan.

Zitieren

APA

Sakai, D., Kaneko, K., Furukawa, K., Kawazoe, M., Matsuzawa, Y., & Nanki, T. (2025). Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study. Rheumatology International. https://doi.org/10.1007/s00296-025-05991-4

Vancouver

Sakai D, Kaneko K, Furukawa K, Kawazoe M, Matsuzawa Y, Nanki T. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study. Rheumatology International. 2025. doi:10.1007/s00296-025-05991-4

BibTeX
@article{Sakai2025,
  author = {Sakai, Daiki and Kaneko, Kaichi and Furukawa, Karin and Kawazoe, Mai and Matsuzawa, Yasuo and Nanki, Toshihiro},
  title = {Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study},
  journal = {Rheumatology International},
  year = {2025},
  doi = {10.1007/s00296-025-05991-4}
}
Kostenlos starten →